NCT04943497 - A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia | Biotech Hunter

Enrollment

3,290

Participants

Timeline

Start Date

July 27, 2021

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions

Breast Cancer

Interventions

OTHER

ribociclib

There is no treatment allocation. Patients administered ribociclib by prescription that have started before inclusion of the patient into the study will be enrolled.

OTHER

aplelicib

There is no treatment allocation. Patients administered aplelicib by prescription that have started before inclusion of the patient into the study will be enrolled.

OTHER

mono endocrine therapy

There is no treatment allocation. Patients administered mono endocrine therapy by prescription that have started before inclusion of the patient into the study will be enrolled.

OTHER

chemotherapy

There is no treatment allocation. Patients administered chemotherapy by prescription that have started before inclusion of the patient into the study will be enrolled.

Trial Locations (40)

111123

RECRUITING

Novartis Investigative Site, Moscow

115478

RECRUITING

Novartis Investigative Site, Moscow

142110

RECRUITING

Novartis Investigative Site, Podolsk

143423

RECRUITING

Novartis Investigative Site, Moscow

153040

RECRUITING

Novartis Investigative Site, Ivanovo

156005

RECRUITING

Novartis Investigative Site, Kostroma

163045

RECRUITING

Novartis Investigative Site, Arkhangelsk

167904

RECRUITING

Novartis Investigative Site, Syktyvkar

170008

RECRUITING

Novartis Investigative Site, Tver'

191104

RECRUITING

Novartis Investigative Site, Saint Petersburg

197758

RECRUITING

Novartis Investigative Site, Saint Petersburg

241028

RECRUITING

Novartis Investigative Site, Bryansk

248007

RECRUITING

Novartis Investigative Site, Kaluga

295023

RECRUITING

Novartis Investigative Site, Simferopol

299045

RECRUITING

Novartis Investigative Site, Sevastopol’

300040

RECRUITING

Novartis Investigative Site, Tula

308010

RECRUITING

Novartis Investigative Site, Belgorod

344006

RECRUITING

Novartis Investigative Site, Rostov-on-Don

357502

RECRUITING

Novartis Investigative Site, Pyatigorsk

360051

RECRUITING

Novartis Investigative Site, Nal'chik

392000

RECRUITING

Novartis Investigative Site, Tambov

394036

RECRUITING

Novartis Investigative Site, Voronezh

410053

RECRUITING

Novartis Investigative Site, Saratov

428020

RECRUITING

Novartis Investigative Site, Cheboksary

430032

RECRUITING

Novartis Investigative Site, Saransk

450054

RECRUITING

Novartis Investigative Site, Ufa

454087

RECRUITING

Novartis Investigative Site, Chelyabinsk

603081

RECRUITING

Novartis Investigative Site, Nizhny Novgorod

614066

RECRUITING

Novartis Investigative Site, Perm

620027

RECRUITING

Novartis Investigative Site, Yekaterinburg

620036

RECRUITING

Novartis Investigative Site, Yekaterinburg

625000

RECRUITING

Novartis Investigative Site, Tyumen

628012

RECRUITING

Novartis Investigative Site, Khanty-Mansiysk

628402

RECRUITING

Novartis Investigative Site, Surgut

630108

RECRUITING

Novartis Investigative Site, Novosibirsk

656045

RECRUITING

Novartis Investigative Site, Barnaul

660022

RECRUITING

Novartis Investigative Site, Krasnoyarsk

664035

RECRUITING

Novartis Investigative Site, Irkutsk

680042

RECRUITING

Novartis Investigative Site, Khabarovsk

690105

RECRUITING

Novartis Investigative Site, Vladivostok